Krystal Biotech filings document formal disclosures for a commercial-stage biotechnology company developing and commercializing genetic medicines. Recent 8-K reports furnish quarterly and annual financial results, VYJUVEK net product revenue updates, Regulation FD clinical materials, FDA-related program updates, and commercial launch information for VYJUVEK in Japan.
The company's proxy materials disclose board and shareholder-vote matters, executive compensation, equity awards, ownership information, and governance practices. Together, the filings record how Krystal reports operating performance, capital resources, pipeline and regulatory disclosures, and public-company governance for its HSV-1-based gene therapy platform.
KRYS affiliate files Form 144 to sell common stock. The filing lists proposed/reported sales by Daniel S. Janney consisting of 37,895 shares, 13,825 shares and 700 shares with aggregate cash proceeds reported as $10,113,354.42, $3,709,850.15 and $192,500, respectively. Dates shown for the transactions are 02/24/2026 and 02/25/2026.
KRYS filing a Form 144 notice reports proposed sales of common stock by Daniel S. Janney. The filing lists a proposed sale of 37,895 shares for $10,113,354.42 and a proposed sale of 13,825 shares for $3,709,850.15, both dated 02/24/2026.
KRYS submitted a Form 144 notifying a proposed sale of Common stock, listing 37,895 shares to be sold through Fidelity Brokerage Services LLC by 02/24/2026 with a sale method labeled Cash.
The filing also shows securities sold during the past three months: 13,825 Common shares by Daniel S. Janney on 02/24/2026 for $3,709,850.15.
KRYS: Form 144 sale notice by Daniel S Janney for $10,113,354.42 proceeds on 02/24/2026. The filing lists the sale of 37,895 common shares and identifies the issuer contact as Merrill Lynch, 555 California Street, San Francisco. The securities trace to a private placement dated 08/25/2017.
Krystal Biotech, Inc. director Dino A. Rossi reported option exercises and related share sales. On February 19, 2026, he exercised stock options for 18,950 shares of common stock at $8.79 per share. The options vested ratably over four years beginning on June 1, 2018. On the same date, he sold 8,116 shares at $260.4858 and 10,834 shares at $262.10 in open-market transactions, totaling 18,950 shares sold. After these trades, he directly owned 78,691 shares of Krystal Biotech common stock.
Krystal Biotech reported strong fourth quarter and full year 2025 results, with full-year product revenue, net of $389.1 million and net income of $204.8 million, or $6.84 per diluted share. Fourth quarter product revenue reached $107.1 million, driving quarterly net income of $51.4 million, or $1.70 per diluted share. The company ended December 31, 2025 with $955.9 million in cash, cash equivalents, and investments, and generated a gross margin of 94% on VYJUVEK revenue. Krystal also highlighted global commercialization progress for VYJUVEK and advancement across its respiratory, ophthalmology, dermatology, oncology, and aesthetics pipelines, including FDA RMAT and Fast Track designations and multiple ongoing or planned registrational studies.
Krystal Biotech, Inc. provides an annual overview of its commercial-stage gene therapy business, centered on its HSV‑1-based redosable platform. The company’s first product, VYJUVEK, is approved in the United States, European Union, and Japan for dystrophic epidermolysis bullosa and has generated $730.3 million in net product revenue since launch.
Krystal is expanding VYJUVEK globally, with launches in Germany, France and Japan and additional distribution agreements across Europe and the Middle East. It reports broad clinical activity across respiratory, ophthalmology, dermatology, oncology and aesthetics programs, including inhaled KB407 for cystic fibrosis, KB408 for alpha‑1 antitrypsin deficiency, ocular candidates KB803 and KB801, dermatology program KB111, oncology asset KB707 for lung cancer, and aesthetic candidates KB304 and KB301.
The company emphasizes in‑house commercial‑scale CGMP manufacturing through its ANCORIS and ASTRA facilities, which support VYJUVEK supply and its broader pipeline. Krystal also highlights a growing global intellectual property estate around its HSV‑1 vector platform, commercial product and pipeline candidates.
Krystal Biotech Chief Accounting Officer Kathryn Romano reported exercising stock options for 12,500 shares of common stock at an exercise price of $63.55 per share on February 9, 2026, then selling the same 12,500 shares in multiple open‑market trades at prices between $270.010 and $277.88 per share. Following these sales, she directly owned 18,568 shares of Krystal Biotech common stock.
The option exercise, share sales, and a 750‑share bona fide gift to a charitable donor‑advised fund were carried out under a pre‑arranged Rule 10b5‑1 trading plan that began on November 6, 2025 and is scheduled to run through August 31, 2026, subject to earlier termination under its terms.
Krystal Biotech common stockholder plans to sell 12,500 shares under Rule 144. The shares are to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $3,458,250 and 28,997,519 shares of Krystal Biotech common stock shown as outstanding.
The seller acquired these 12,500 shares on 02/09/2026 through the exercise of a stock option originally granted on 02/28/2022, paying cash for the shares. The notice includes a representation that the seller is not aware of any undisclosed material adverse information about Krystal Biotech’s current or prospective operations.